Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients.
Anurag MehtaMumtaz SaifiUllas BatraM SuryavanshiKush GuptaPublished in: Lung Cancer (Auckland, N.Z.) (2020)
ROS1-gene rearrangement was present at a relatively higher frequency of 2.8% in north Indian patients with lung adenocarcinoma and was successfully targeted by crizotinib therapy. Although the only US Food and Drug Administration and Conformité Européenne approved method for testing ROS1 rearrangement is NGS, FISH alone or IHC with D4D6 antibody as initial screen with subsequent confirmation of IHC-positive cases by FISH are cost-effective methods in institutions lacking NGS facilities.
Keyphrases
- drug administration
- cell death
- dna damage
- reactive oxygen species
- ejection fraction
- newly diagnosed
- advanced non small cell lung cancer
- single cell
- risk factors
- prognostic factors
- high throughput
- gene expression
- stem cells
- oxidative stress
- copy number
- dna methylation
- human health
- bone marrow
- drug delivery
- genome wide identification